SPY411.45-1.41 -0.34%
DIA337.53+0.74 0.22%
IXIC13,857.84-138.26 -0.99%

IMV: Phase 2B Clinical Trial in Patients With Relapsed /refractory DLBCL Expected to Be Initiated in Q2 2021 Following Guidance Received From the FDA >IMV.T

IMV: Phase 2B Clinical Trial in Patients With Relapsed /refractory DLBCL Expected to Be Initiated in Q2 2021 Following Guidance Received From the FDA >IMV.T

· 03/17/2021 07:05

Please log in to view news